Relationship between Certain Hematological Parameters and Risk of Breast Cancer

Zhang, Xuan; Tan, Xiaodan; Li, Junhong; Wei, Zhixiao

doi:10.2217/fon-2022-0589

Cited by 2 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a meta-analysis by Chi et al, a low HRR was associated with an increased risk of all-cause mortality (hazard ratio [HR] 2.29) and disease progression or relapse (HR 2.19). Additionally, the diagnostic efficacy of HRR for breast, nasopharyngeal, and lung cancers has been reported 17 , 22 , 23 . However, the diagnostic efficacy of HRR for OCs has not been reported.…”

Section: Discussionmentioning

confidence: 99%

“…The HRR is a prognostic marker for various malignant tumors [17][18][19][20][21]. In a meta-analysis by Chi et al, a low HRR was associated with an increased risk of all-cause mortality (hazard ratio [HR] 2.29) and disease progression or relapse (HR 2.19).…”

Section: Discussionmentioning

confidence: 99%

“…Red cell distribution width (RDW) predicts ovarian cancer (OC) with an SE and SP of 76.7% and 70.3%, respectively [16]. Recently, the Hb-to-RDW ratio (HRR) has been reported to be a prognostic marker for malignant tumors, including head and neck cancer, lung cancer, esophageal cancer, gastric cancer, hepatoma, renal cell carcinoma, bladder cancer, and malignant lymphoma [17][18][19][20][21]. Additionally, the diagnostic efficacy of HRR for breast, nasopharyngeal, and lung cancers has been reported [17,22,23].…”

Section: Introductionmentioning

confidence: 99%

“…Recently, the Hb-to-RDW ratio (HRR) has been reported to be a prognostic marker for malignant tumors, including head and neck cancer, lung cancer, esophageal cancer, gastric cancer, hepatoma, renal cell carcinoma, bladder cancer, and malignant lymphoma [17][18][19][20][21]. Additionally, the diagnostic efficacy of HRR for breast, nasopharyngeal, and lung cancers has been reported [17,22,23]. However, the clinical value of HRR in gynecological malignancies remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses

Jang¹,

Kim²,

Eo³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Background : This study aimed to determine the optimal combination of biomarkers that can predict epithelial ovarian cancer (EOC) and compare the combination with the risk of ovarian malignancy algorithm (ROMA) or Copenhagen index (CPH-I). Methods : Data from 66 patients with EOC and 599 patients with benign ovarian masses who underwent definitive tissue diagnosis of adnexal masses between January 2017 and March 2021 were analyzed. The Mann-Whitney U test or Kruskal-Wallis test was used for between-group comparisons of medians. Logistic regression was used to establish an EOC predictor model. Area under the curve (AUC) comparisons between models were performed using the Delong nonparametric approach. Results : The median age of the patients was 43 years. Twenty-nine (43.9%) patients had early-stage disease (stages I-II) and 37 (56.1%) patients had advanced-stage disease (stages III-IV). The median age, body mass index, white blood cell count, hemoglobin-to-red cell distribution width ratio (HRR), platelet count, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, serum albumin level, cancer antigen 125, human epididymal secretory protein 4 (HE4), ROMA, and CPH-I were significantly different between the stage I-IV EOC and benign ovarian mass groups. Multivariate logistic regression analysis revealed that HE4, HRR, and computed tomography (CT) imaging were significant predictors of both stages I-IV and I-II EOC. Using these covariates, an interim model (IM) (consisting of HE4 and HRR) and a full model (FM) (consisting of HE4, HRR, and CT imaging) were constructed. When predicting stage I-IV EOC, the AUC of IM was comparable to that of ROMA or CPH-I, whereas the AUC of FM outperformed ROMA or CPH-I. In predicting stage I-II EOC, the AUC of IM was comparable to that of CPH-I but higher than that of ROMA, and the AUC of FM outperformed ROMA or CPH-I. Conclusion : FM outperformed ROMA or CPH-I in predicting stage I-IV EOC and stage I-II EOC. Therefore, FM could be a promising model for improving preoperative prediction of EOC at an early stage. However, further prospective studies are required to validate these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses

Jang¹,

Kim²,

Eo³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

show abstract

“…These associations were observed across all included cancer types aside from head and neck carcinoma. However, Tham et al reported that the Hb/RDW ratio was independently related to event-free survival (EFS, p = 0.017) [42,43,[72][73][74][75].…”

Section: Prognostic Value Of Hb/rdwmentioning

confidence: 99%

Assessing the Predictive Power of the Hemoglobin/Red Cell Distribution Width Ratio in Cancer: A Systematic Review and Future Directions

Coradduzza,

Medici,

Chessa

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: The hemoglobin (Hb)/red cell distribution width (RDW) ratio has emerged as an accessible, repeatable, and inexpensive prognostic factor that may predict survival in cancer patients. The focus of this systematic review is to investigate the prognostic role of the Hb/RDW ratio in cancer and the implications for clinical practice. Materials and Methods: A literature search of PubMed, Scopus, and Web of Science databases was performed by an independent author between 18 March and 30 March 2023 to collect relevant literature that assessed the prognostic value of the Hb/RDW ratio in cancer. Overall survival (OS), progression-free survival (PFS), and the association of these with the Hb/RDW ratio were considered to be the main endpoints. Results: Thirteen retrospective studies, including 3818 cancer patients, were identified and involved in this review. It was observed that, when patients with a high vs. low Hb/RDW ratio were compared, those with a lower Hb/RDW ratio had significantly poorer outcomes (p < 0.05). In lung cancer patients, a one-unit increase in the Hb/RDW ratio reduces mortality by 1.6 times, whilst in esophageal squamous-cell carcinoma patients, a lower Hb/RDW ratio results in a 1.416-times greater risk of mortality. Conclusions: A low Hb/RDW ratio was associated with poor OS and disease progression in patients with cancer. This blood parameter should be considered a standard biomarker in clinical practice for predicting OS and PFS in cancer patients. Future searches will be necessary to determine and standardize the Hb/RDW cut-off value and to assess whether the Hb/RDW ratio is optimal as an independent prognostic factor or if it requires incorporation into risk assessment models for predicting outcomes in cancer patients.

show abstract

Relationship between Certain Hematological Parameters and Risk of Breast Cancer

Cited by 2 publications

References 25 publications

Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses

Clinical Significance of the Combination of Serum HE4 Levels, Hemoglobin-to-Red Cell Distribution Width Ratio, and CT Imaging for the Pretreatment Assessment of Adnexal Masses

Assessing the Predictive Power of the Hemoglobin/Red Cell Distribution Width Ratio in Cancer: A Systematic Review and Future Directions

Contact Info

Product

Resources

About